Gutscheinbedingungen

*Gültig bis 07.06.2026 auf (fast) alles. Ausgeschlossen sind Smartboxen, Zeitschriften, Tickets, Lebensmittel, Gaming-Elektroartikel, Tinte/Toner, Gutscheine, Geschenkkarten, Blumen und Abos | Einlösbar in allen Buchhandlungen von Orell Füssli, Barth Bücher, Buchladen Rapunzel, Schuler Orell Füssli, Stauffacher und ZAP unter Vorweisung des Gutscheins, auf www.orellfüssli.ch durch Eingabe des Gutscheincodes. Beim Service „eBooks verschenken“ und bei eBook-Käufen via eReader nicht einlösbar | Mindesteinkaufswert: Fr. 100.- | Nicht mit anderen Rabatten kumulierbar.

Produktbild: Natural Product-based Synthetic Drug Molecules in Alzheimer's Disease

Natural Product-based Synthetic Drug Molecules in Alzheimer's Disease Therapeutic & Theranostic Agents

Fr. 218.00

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

16.12.2023

Herausgeber

Abha Sharma + weitere

Verlag

Springer Singapore

Seitenzahl

447

Maße (L/B/H)

24.1/16/3.1 cm

Gewicht

857 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-981-9960-37-8

Beschreibung

Portrait

Dr. Abha Sharma  is working as an associate professor in the department of medicinal chemistry at National Institute of Pharmaceutical Education and Research, Raebareli, India. She earned her Ph.D. from the Defence Research and Development Establishment (awarded by Jiwaji University), Gwalior, India, 2006. She has worked at Indian Institute of Toxicology Research (IITR), Lucknow as a research associate for more than three and a half years. Her research area includes design and synthesis of molecules for the treatment of Alzheimer’s disease and the development of sensors/probes for the detection of analytes/biomarkers of central nervous system diseases like AD. She published more than 40 papers in high-impact journals, several book chapters, and filed patents. She has served as a referee for a number of international journals and several students have completed their research projects under her guidance.

Dr. Gyan Prakash Modi  is working as an assistantprofessor in the department of pharmaceutical engineering and technology, Indian Institute of Technology (BHU), Varanasi, India. He earned a Ph.D. from the department of pharmaceutical sciences, Wayne State University, Detroit, Michigan, USA, in 2013, followed by postdoctoral training at Brandeis University, Waltham, Massachusetts, USA. His research area includes drug development for neurodegenerative diseases, inhibitor design, and the development of novel (near-infrared) NIR probes targeting various chronic central nervous system diseases like Alzheimer's disease (AD). He published nearly 25 research papers in high-impact journals and filed several patents, including four US patents in medicinal chemistry. He has been selected as a young investigator to attend YIM 2019 organized by India Bioscience at IIT Guwahati, he is also the recipient of several awards including outstanding scientist in medicinal chemistry, Venus international foundation.

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

16.12.2023

Herausgeber

Verlag

Springer Singapore

Seitenzahl

447

Maße (L/B/H)

24.1/16/3.1 cm

Gewicht

857 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-981-9960-37-8

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: ProductSafety@springernature.com

Kundinnen und Kunden meinen

0 Bewertungen

Informationen zu Bewertungen

Zur Abgabe einer Bewertung ist eine Anmeldung im Konto notwendig. Die Authentizität der Bewertungen wird von uns nicht überprüft. Wir behalten uns vor, Bewertungstexte, die unseren Richtlinien widersprechen, entsprechend zu kürzen oder zu löschen.

Die Bewertungen sind nach Format, Anzahl Sterne und Datum sortiert.

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kund*innen durch Ihre Meinung

Kundinnen und Kunden meinen

0 Bewertungen filtern

  • Produktbild: Natural Product-based Synthetic Drug Molecules in Alzheimer's Disease
  • Section 1: Introduction of Alzheimer’s Disease.- Chapter 1: Alzheimer’s disease and drug targets.- Chapter 2: Oxidative stress and metals in Alzheimer’s disease.- Chapter 3: Neuroinflammation in Alzheimer’s disease.- Section 2:  Biomarkers and Diagnosis in Alzheimer’s Disease.- Chapter 4: Biomarkers of Alzheimer’s disease.- Chapter 5: Naturally inspired fluorescent organic molecules as diagnostic and theranostic tools in Alzheimer’s disease.- Chapter 6: Nanostructure-based molecules as diagnostic and theranostic tools in AD.- Section 3:  Drug derivatives: A strategy for new multifunctional drug development for Alzheimer’s Disease.- Chapter 7: Approved cholinesterase inhibitors-based derivatives: Synthesis and their biological evaluation.- Chapter 8: Memantine-based derivatives: Synthesis and their biological evaluation.- Section 4: Natural molecules inspired novel derivatives for Alzheimer’s Disease.- Chapter 9: Huperzine-based derivatives: Design, synthesis, and anti-Alzheimer activity.- Chapter 10: Polyphenol: Development of polyphenol-inspired derivatives targeting pathological factors of AD.- Chapter 11: Flavonoid-based derivatives for modulating various targets of Alzheimer’s disease.- Chapter 12: Vitamin-based derivatives for the management of Alzheimer’s disease.- Section 5: Metal dyshomeostasis: A hypothesis for developing drugs for the treatment of Alzheimer’s disease.- Chapter 13: Metal chelators as a potential therapeutic agent for Alzheimer’s disease.- Chapter 14: Ferroptosis modulators: A potential therapeutic target in Alzheimer’s disease.- Section 6. Natural products/Synthetic molecules as epigenetic modulators in Alzheimer’s disease.- Chapter 15. Sirtuin modulator: Design, synthesis, and biological evaluation.- Chapter 16. Histone deacetylase Inhibitors: Design, synthesis, and biological evaluation.